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Synopsis (1-paragraph) 
Feline infectious peritonitis (FIP) is a common differential for disease in, often younger, cats. Obtaining a 
definitive diagnosis by minimally-invasive means can be challenging, and a balance of probability might 
need to be used to guide further investigation or treatment. Although treatment is currently limited, novel 
anti-viral agents show real promise for the future. 
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Key Points  
• Appreciation of the relationship between feline coronavirus (FCoV) and feline infectious peritonitis 
(FIP) is vital in interpreting guidance on diagnosis, treatment and prevention 
• Presumptive diagnosis in most cases is relatively straightforward; however, achieving confidence 
in a diagnosis in some cats is more complex as is definitive confirmation of FIP 
• Molecular diagnostics (especially FCoV-targeted reverse-transcriptase quantitative polymerase 
chain reaction on tissue or effusion samples) can increase our confidence in a diagnosis of FIP, 
but an appreciation of their methodology is necessary to understand their limitations 
• Recently some novel therapeutics have been shown to be effective in the treatment of FIP (viral 




Feline coronavirus (FCoV) is ubiquitous worldwide. Infection is common among the domestic cat 
population, usually only causing mild enteric signs (e.g. diarrhea). In a small percentage of FCoV-infected 
cats, viral mutations, systemic spread and aberrant immune response results in a syndrome of serositis, 
vasculitis and pyogranulomatous lesions known feline infectious peritonitis (FIP). A presumptive diagnosis 
of FIP is often made in sick, particularly young, cats with the effusive disease; however, variability in 
presentation and test limitations can make obtaining a definitive diagnosis or even a presumptive 
diagnosis using non- or minimally-invasive approaches difficult. In the absence of treatment using novel 
anti-viral agents, FIP is fatal in the overwhelming majority of cases.  
 
Viral properties 
• FCoV is an enveloped, single-stranded, positive-sense RNA coronavirus of the Alphacoronavirus 
genus (Figure 1) 
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o Other viral species within this genus include transmissible gastroenteritis virus (TGEV) in 
pigs, canine coronavirus (CCoV) in dogs and human coronaviruses (HCoV-NL63; HCoV-
229E) 
o Human pathogens severe acute respiratory syndrome-coronavirus (SARS-CoV), Middle East 
respiratory syndrome-coronavirus (MERS-CoV), and SARS-CoV-2 (the cause of COVID-19) 
are of the Betacoronavirus genus 
• Coronavirus genomes are relatively large (for an RNA virus) (Figure 2)1 and encode: 
o A large, non-structural polyprotein (pp1a; pp1ab), which is cleaved into smaller proteins 
(including proteases and the viral RNA polymerase) 
o Spike (S) glycoprotein – a trimeric transmembrane protein involved in host-cell receptor 
binding and cell entry; forms part of the viral envelope 
o Envelope (E) protein – forms part of the viral envelope 
o Membrane (M) protein (a.k.a. Matrix protein) – forms part of the viral envelope 
o Nucleocapsid (N) protein – interacts with the viral genomic RNA 
o Non-structural proteins (3abc and 7ab) – the function of these proteins is poorly understood; 
however, it is suspected that they play a role in viral replication and release, as well as 
interfering with the host cellular response to infection (e.g. inhibition of apoptotic pathways) 
• Like other RNA viruses, FCoV exhibits a high rate of mutation during replication and exist as clusters 
of genetically diverse populations 
• FCoV infects domestic and wild felids 
o FCoV is not transmissible to humans 
• Two biotypes of FCoV are described 2, 3: 
o Feline enteric coronavirus (FECV) – the ‘avirulent’ enteric form of FCoV; replicates mainly 
within enterocytes; can cause enteric clinical signs; is shed in feces 
o Feline infectious peritonitis virus (FIPV) – the ‘virulent’ systemic form of FCoV; replicates 
within monocytes and tissue macrophages, leading to systemic spread; results in the 
development of FIP in a minority of infected cats; shedding in feces is possible  
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o FIPV is considered to arise from FECV as a result of mutation within individual cats (‘internal 
mutation’ hypothesis in comparison to the ‘distinct circulating avirulent and virulent strains’ 
hypothesis) 
o Genetic analysis of FIPV isolates reveal them to be most closely related to the FECV from 
which they arose (rather than to other FIPV isolates) 
• Two serotypes of FCoV exist: 
o Type 1 – predominates worldwide; difficulties in cultivation in vitro have limited research 
o Type 2 – arose following genetic recombination between FCoV and CCoV; genetic analyses 
have demonstrated that this has occurred on multiple separate occasions 4-6; extensively 
studied as can be cultured in vitro 
o Serotypes are differentiated primarily based upon the S glycoprotein, either by the 
immunological response they trigger (e.g. detection of virus neutralizing antibodies) 3, or more 
recently, by gene amplification and sequencing (as the change in antigenicity is due to 
genetic recombination detectable through this method) 7 
o Infection with either serotype has been associated with both enteric disease and FIP, 
therefore either serotype can be present as either biotype 
• Feline infection with other coronaviruses 
o Following detection of antibody cross-reactivity between closely related coronavirus species 
(incl. FCoV serotypes 1 & 2, CCoV, and TGEV) 8, 9, the potential role of cats as a vector of 
these infections or whether exposure to these infections conferred either protection against or 
enhancement of subsequent infection with FCoV was explored in early experimental studies 
o Following exposure to TGEV cats developed transient, subclinical infection with shedding in 
feces 10, 11; cross-reactive antibodies were produced; protection against infection with FCoV, 
and subsequent development of FIP, was not documented 
o Following exposure to CCoV cats developed transient, subclinical infection with no fecal 
shedding detected 12; cross-reactive antibodies were produced; neither protection against nor 
antibody-dependent enhancement (ADE) of infection with FCoV (and subsequent 
development of FIP) was documented 
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o Exposure to HCoV 229E did not result in clinical signs, nor the production of cross-reactive 
antibodies, although virus-specific antibodies were produced 13; neither protection against nor 
ADE of infection with FCoV (and subsequent development of FIP) was documented 
 
Prevalence 
• FCoV is found in cats worldwide, other than on a small number of isolated islands 
• FCoV frequently circulates in multicat households 
o Seroprevalence (reviewed elsewhere 14): is significantly greater in multicat households (26-
87%) than in single-cat households (4-24%) 
o In environments in which FCoV is endemic, most cats experience repeated cycles of infection 
and subsequent viral elimination 15, 16 
o In some cats, the initial infection persists and is chronic (+/- intermittent) shedding may occur 
16, 17 
• Incidence of FIP is low in comparison: 
o 1 in 5000 cats affected in one or two cat households 
o 5-10% of cats affected in some catteries 18, 19 
o FIP is usually sporadic; rarely epidemics can occur, and can possibly be explained by a 
combination of:  
▪ High population density settings (e.g. breeding catteries; rescue shelters; feral cat 
populations) 
▪ Shared genetic background 
▪ Shared challenges to immune function (e.g. stress; limited resources) 
▪ Shared viral factors 
 
FIP risk factors 
• Some of the risk factors for the development of FIP likely relate to risk factors for FCoV infection 
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• Some studies have indicated increased risk of FIP in multicat households; however, a recent study 
noted that the majority of cats were living in a single- or two-cat households at the time of diagnosis 
20, although this would not necessarily have reflected their situation at time of exposure to FCoV 
• Male cats are at slightly higher risk of FIP 20 
• Genetic susceptibility 
o Siblings of cats with FIP are considered to be at increased risk of developing FIP (~2x risk) 
o Some studies have indicated increased risk in specific pedigree breeds 21, 22; however, this is 
not borne-out by every study 20. and there was geographical variation in the breeds identified 
as increased risk 21, 22. In addition there may be a degree of reporting bias (positive and 
negative) from the cat fancy community 
• There is an increased incidence of FIP in kittens and young adult cats (55% cases  2 years), with a 
secondary peak in older cats (>10 years). However, FIP can affect cats of all ages 
o Experimental work has shown that resistance to infection increases from 6 months’ age to >1 
year 23 
• Stress is often a prominent historical feature e.g. recent rehoming, neutering, vaccination etc. 
 
Transmission 
• FECV is transmitted horizontally between cats, primarily via the feco-oral route 
o Litter trays are the primary source of infection 
o Contaminated fomites (e.g. grooming equipment; soft furnishings) may also play a role 
• Oronasal route, via saliva and respiratory secretions, may also play a role 24, 25; however, further 
investigation is required to characterize this further 
• Whether fecally-shed FIPV shed is competent of horizontal transmission of is unclear 26 
• Vertical transmission in utero (i.e. of FIPV from the queen with FIP to her kitten(s)) is considered 
possible but rare 27, 28 
• Iatrogenic transmission, via parenteral injection or aerosolization of FIPV derived from cats with FIP, 
has been demonstrated experimentally 13, 29 
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• In large, endemically-infected, multi-cat households, kittens commonly become infected at a young 
age, mostly at 5-6 weeks, as maternally-derived-antibodies (MDA) wane below protective levels 18 
o The queen is suspected to be the most common source of infection, followed by other 
breeding or non-breeding cats (especially older litters of kittens) 
• FCoV survives 1-2 days at room temperature; but may survive up to 7 weeks in a dry environment 
(e.g. in feces) 30; Fuller’s earth-based cat litters appeared to be most effective at inactivating FCoV in 
vitro, but they failed to prevent transmission in vivo 31 
• FCoV is inactivated by most disinfectants 
 
Pathogenesis 
• The exact pathogenesis of the development of FIP is still under investigation 
• It suspected that FCoV strains of variable virulence, or variable potential for virulence, are circulating 
in the general feline population; this could, in part, account for some outbreaks 
• Ingestion of FCoV (as FECV) → small intestinal villi enterocytes are the primary site of host cell entry, 
with spread to colonic enterocytes 
o Viral spike protein binds to serotype-specific cell entry receptors → internalization of virus 
▪ The cell receptor for serotype 1 FCoV is unknown  
▪ Aminopeptidase N (APN; CD13) is the cell receptor for serotype 2 FCoV, for 
macrophages at least 32 
o Replication within enterocytes 
▪ Local inflammatory reaction → immune response → infection may be cleared or 
persist in chronic infections (esp. in colonic enterocytes) 
▪ Shedding in feces within 7 days → duration of shedding is highly variable (weeks; 
months; lifelong) 17 
o Intestinal macrophages acquire FCoV from infected enterocytes 33 (exact mechanism 
unknown) → regional lymph nodes (e.g. mesenteric) → monocyte-associated viremia in most 
cats 34, 35 
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o FCoV mutates (i.e. FECV → FIPV), resulting in progressive acquisition of enhanced tropism 
for, and increased ability to replicate within, monocytes / macrophages → further systemic 
spread (monocyte-associated viremia) 
o In an estimated 10% of cats with systemic FCoV (as FIPV) infection 36, an aberrant immune 
response develops whereby activated monocytes / macrophages infected with FCoV interact 
with endothelial cells 37 → granulomatous phlebitis and periphlebitis = FIP 
• FCoV has also been detected in conjunctival, nasal, and oropharyngeal tissue 25; its role in upper 
respiratory tract disease is unknown 
• Role of the host immune-response in FIP pathogenesis 38 
o A poor cell-mediated immune response results in vasculitis, particularly affecting serosal 
surfaces; this vasculitis / serositis leads to fluid accumulations in one or more body cavity (i.e. 
peritoneal > pleural > pericardial) and is termed effusive FIP 
o A partial cell-mediated immune response leads to pyogranulomatous or granulomatous 
lesions in organs (often kidneys, liver, lungs, eyes, CNS, mesenteric LNs and gastro-
intestinal tract), and in the absence of effusions is termed non-effusive FIP 
o These likely reflect a continuum: 
▪ Some cats with initially non-effusive disease will develop effusions 
▪ Cats with effusive disease often have granulomas present in parenchymal organs 
• Viral factors in FIP pathogenesis: 
o Viral mutations 
▪ Spike gene 
• Functional mutations (M1058L and S1060A) within the putative fusion 
peptide of serotype 1 FCoV were able to differentiate 95.8% isolates of 
FECV and FIPV in one study 39; the FCoV isolates used were either tissue-
derived from cats with FIP (i.e. FIPV) or feces-derived from healthy cats (i.e. 
FECV). This led to the suggestion that presence of either functional mutation 
is diagnostic for FIP (see FCoV mutation analysis and Table 3). A more 
recent study found that 12 of 45 (26.7%) cats without FIP had at least one 
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tissue or effusion sample that was positive for FCoV, and of the 18 samples 
from these 12 cats where Spike gene sequencing was successful 16 (88.9%) 
had functional mutations consistent with FIPV 7 
• Functional mutations within the putative furin cleavage site of serotype 1 
FCoV were able to differentiate 92.7% isolates of FECV and FIPV in another 
study 40; again, the FCoV isolates used were either tissue-derived from cats 
with FIP or feces-derived from healthy cats 
▪ Non-structural protein 3c gene – mutations encoding a truncated protein are present 
approximately 2 in 3 cats with FIP, whereas the 3c genes are intact in cats without 
FIP 41-43; again, the FCoV isolates used were either tissue-derived from cats with FIP 
or feces-derived from healthy cats. This has led to the conclusion that intact 3c is a 
requirement for enterocyte infection, but not systemic spread. 
▪ Non-structural protein 7b gene – mutations are present in FCoV derived from both 
cats with FIP and cats without FIP; their role in the development of FIP is unknown 
o Viral mutations are thought to occur during bursts of viral replication (e.g. following a period of 
immunosuppression) 
o Some cats experience waves of clinical disease (e.g. fever and weight loss) that coincide with 
T-cell depletion and increased viral loads in the blood 38 
o Acquired mutations are also suspected to have a role in tissue tropism – a functional genetic 
mutation in the Spike gene was only found in viral RNA extracted from the neurological tissue 
of a cat with neurological FIP but not in viral RNA extracted from other organs from the same 
cat 44. The same mutation was found in FCoV purified from the neurological tissue from 
another cat with neurological FIP 
 
Clinical signs of enteric FCoV infection 
• Often subclinical 
• Replication within enterocytes may cause mild enteric-associated signs (e.g. inappetence, diarrhea, 
vomiting); rarely causes severe enteritis 
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• FCoV has been detected in conjunctival, nasal, and oropharyngeal swab samples in cats with upper 
respiratory tract signs 25; however, the role of FCoV in upper respiratory tract disease requires further 
investigation 
 
Clinical signs of FIP 
• Two clinical variants of FIP disease are recognized 
o Effusive (‘wet’) form – where effusions develop in one or more body cavity as a result of 
vasculitis/serositis; accounts for ~80% of cases of FIP 20 
o Non-effusive (‘dry’) form – where pyogranulomatous lesions are present in one or more 
parenchymal tissue 
o At post-mortem examination this distinction is often less clear, with many cats diagnosed with 
effusive disease having pyogranulomatous lesions within parenchymal tissue, and some cats 
diagnosed with non-effusive disease having clinically inapparent effusions present 
• The incubation period, from initial FCoV infection to development of FIP is highly variable; clinical 
signs of effusive disease typically present earlier than those of non-effusive disease 45 
o Following parenteral administration of FIPV, clinical signs of effusive disease developed after 
2-14 days, whilst it took several weeks for clinical signs of non-effusive disease to develop  
o In specific-pathogen-free (SPF) cats, infected ‘naturally’ by exposure to cats known to be 
shedding FCoV, the first clinical signs of FIP occurred from 6 weeks post-exposure 46 
o MDA against FCoV typically decline at around 4-8 weeks age; but kittens as young as 2-
weeks of age have been diagnosed with FIP (based upon either histological diagnosis or 
effusion analysis with immunostaining) although it is not known how these kittens acquired 
FCoV nor whether they had MDA 20 
• Effusive disease typically progresses more rapidly than non-effusive disease 
o 6 to 42 days (average, 14 days) from onset of clinical signs to death in naturally-infected SPF 
cats with effusive disease compared with weeks to months for non-effusive disease [34] 
o When FIP is a differential diagnosis, a careful search for cavitary effusions should be made 
(and likely repeated if initially unsuccessful; especially following rehydration) 
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o The non-effusive form of FIP is typically more difficult to diagnose 
o Cats with effusive disease (cf. non-effusive disease) are: more likely to have pyrexia, 
lymphopenia, and icterus; and less likely to have ocular or neurological signs, azotemia and 
hyperproteinemia 20, 45 
• The range of presenting signs and abnormalities on physical examination associated with FIP are 
variable due to the number(s) and type of organs involved in individual patients 20, 45 
o Non-specific signs including pyrexia (non-responsive to antibiotics), lethargy and inappetence 
are common, although some cats remain bright until the fulminant stages of disease 
o Icterus of sclera and mucous membranes (often mild) 
o Mucous membrane pallor, due to anemia (often mild) 
o Abdominal distention, associated with ascites and /or abdominal organomegaly (often 
representing mesenteric lymphadenopathy, gastro-intestinal masses with focal infiltration, or 
renomegaly) 
o Respiratory signs (including dyspnea, tachypnea, and cough) may be associated with pleural 
effusion and / or pulmonary infiltration (NB: pericardial effusions are sometimes seen, but are 
rarely associated with cardiac tamponade) 
o Evidence of ocular involvement: uveitis (keratic precipitate formation, anisocoria, dyscoria 
and blepharospasm); chorioretinitis with perivascular cuffing; retinal detachment (→ acute 
loss of vision); hyphema; hypopyon 
o Neurological signs, attributed to meningoencephalitis or meningomyelitis, with or without 
obstructive hydrocephalus, are often multifocal and can include ataxia, seizures, vestibular 
signs (e.g. head tilt, nystagmus), cranial nerve deficits, and behavioral change (e.g. 
obtundation) 
o Cutaneous lesions (rare), due to perivascular pyogranulomatous dermatitis, include papular, 
non-pruritic lesions 
 




o The uses and limitations of serological testing of cats for coronavirus antibodies has been 
extensively reviewed elsewhere 47, 48 
o Antibodies may be detected in serum by ELISA (e.g. FCoV/FIP Immunocomb, Biogal), 
immunofluorescence antibody test (IFAT, various), or immunochromatographic test (e.g. 
Speed F-Corona, Virbac) 
▪ Some of these assays (e.g. FCoV/FIP Immunocomb; Speed F-Corona) are point-of-
care and give qualitative or semi-quantitative results; most are very sensitive to 
detect even low antibody titers 49 
▪ Other assays (typically offered by commercial laboratories) give quantitative results, 
that can facilitate monitoring over time; due to potential of variation between 
laboratories it is important that the same laboratory is used when comparing results 
▪ Coronavirus IFAT comprise virus-infected cells fixed upon slides onto which test sera 
are applied; a secondary fluorophore-labeled antibody is then used to determine the 
presence of bound antibodies 
▪ Coronavirus ELISAs or immunochromatographic tests comprise viral antigen bound 
to membranes across which test sera are washed and bound antibodies detected 
using a secondary labelled antibody 
▪ There is marked antibody cross-reactivity between closely related coronavirus 
species, as detected by IFATs based upon TGEV and FCoV (serotypes 1 & 2) 8, 9 
• This property has been exploited by IFATs used to investigate the 
serological antibody response during the development of FIP: feline cells 
infected with either serotype 1 or serotype 2 FCoV can be used, or, 
alternatively, porcine cells infected with TGEV 50 
• Although, it is likely that seropositive cats will have been exposed to 
FCoV cf. another coronavirus, this cannot be assumed; seropositive cats 
are often described as being coronavirus-positive rather than FCoV-
positive 
o Seroconversion occurs 2-3 weeks following exposure to FCoV 51 
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o A high antibody titer (>1:1600) is a non-specific finding of limited value in the diagnosis of 
FIP, especially in cats from multicat households where the likelihood of seropositivity is high, 
in young cats where MDA may persist (up to 12-14 weeks) or in cats with recent exposure to 
others with known FCoV infection (e.g. another cat with FIP in the household) 52, since most 
of these cats will not go on to develop FIP 
o A high antibody titer in association with compatible clinical signs, history etc. can be 
supportive of FIP particularly when coming from a household where the likelihood of 
seropositivity is low (e.g. few cats resident), in that it indicates the necessary exposure to 
FCoV 
o Approximately 10% of cats with fulminant FIP may have negative serology due to peracute 
disease (seroconversion takes 2-3 weeks), immune-complex formation or 
immunosuppression 53 
o A positive antibody titer in a healthy cat does not indicate whether or not they are shedding 
FCoV in their feces 15, 54. During an 8-month observation period, of 24 clinically normal cats 
with high FCoV antibody titers (1:1600) one frequently (>75% of samples) shed FCoV, 20 
occasionally shed FCoV and 3 did not shed 55. Within five breeding catteries where FCoV 
was endemic, between 35% and 70% of cats were shedding at any one time 55 
• Fecal reverse transcriptase-(quantitative) polymerase chain reaction (RT-(q)PCR) (see also Box 1) 
o RT-PCR may be used to detect, and in some cases quantify (i.e. RT-qPCR), FCoV shedding 
in feces 
o Intermittent fecal shedding of FCoV or laboratory error (e.g. due to carry-over of PCR 
inhibitors found in feces) can result in negative results 56 
o Repeated testing is required to identify persistent or recurrent FCoV shedders in multi-cat 
households, or whether they have stopped shedding. The optimum frequency of sample 
collection is unknown 
o A positive RT-PCR result does not indicate whether a cat has, or will go on to develop FIP 
 
Diagnosis of FIP 
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See Figure 3 for a suggested approach cats suspected of having FIP 
• Definitive diagnosis of FIP ante-mortem can be challenging, and:  
o Some consider histological co-localization of pyogranulomatous inflammation with presence 
of FCoV (demonstrated by immunostaining for FCoV antigen) within monocytes / 
macrophages necessary to make a definitive diagnosis of FIP, and this is frequently 
considered the reference standard in studies evaluating diagnostic techniques 7, 57; however, 
this necessitates performance of procedures, of variable degrees of invasiveness, to obtain 
diagnostic samples 
o In contrast, for many clinical trials and some trials of diagnostic techniques, diagnosis has 
been made based upon a combination of signalment, clinical history, physical examination 
and clinicopathological findings (sometimes, but not always including RT-(q)PCR or 
immunostaining of tissue or effusions) 58-60  
• Ante-mortem a clinical diagnosis of FIP is more often based on the combination of compatible 
signalment, history, clinical signs, typical clinical pathology changes (see Clinical pathological 
changes of FIP), analysis of effusions (if present; see Effusion analysis), and analysis of other 
cytological samples (see Analysis of cytological samples other than effusions) 
o Identification of FCoV within effusions, tissue aspirates, cerebrospinal fluid (CSF) etc., either 
by immunostaining for FCoV antigen (see Immunostaining for FCoV antigen) or by RT-
(q)PCR (see Molecular diagnostics in the diagnosis of FIP and Box 1) for genetic sequences 
of FCoV can be strongly supportive 
o In some cats, tissue biopsy (see Tissue biopsy analysis) may be required to provide sufficient 
support for a clinical diagnosis of FIP 
o The use of machine-learning techniques to enhance interpretation of combinations of data 
and indicate likelihood of disease are likely to be developed over the coming years 61 
• Imaging modalities (e.g. thoracic or abdominal ultrasound; radiography; computed tomography; 
magnetic resonance imaging) can reveal evidence of fluid accumulations, mass lesions, and 
vasculitis / inflammation 
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o No imaging sign is pathognomonic for FIP, but imaging can facilitate exclusion of other 
differential diagnoses 
o Imaging may facilitate needle sampling for further diagnostics, e.g. cytology 
o Fluid accumulations may progress over time, particularly following correction of dehydration, 
such that repeated imaging may be required 
 
Clinical pathological changes of FIP 20, 45 
• Hematology – changes, if present, are non-specific, but could include: 
o Mild, non-regenerative anemia (common) 
o Severe, regenerative anemia due to immune-mediated hemolytic anemia or hemorrhage 
(uncommon) 
o Microcytosis in the absence of anemia (common) 
o Mild neutrophilia, with or left shift or toxic changes (common); neutropenia (uncommon) 
o Lymphopenia (common); lymphocytosis (uncommon) 
o Eosinopenia (common); eosinophilia (uncommon)  
o Monocytosis (common) 
o Thrombocytopenia, due to consumptive or immune-mediated processes (common); 
thrombocytosis (uncommon) 
o Increased coagulation test parameters (e.g. activated partial thromboplastin time, aPTT; 
prothrombin time, PT) may develop due to consumptive processes in fulminant FIP (e.g. 
disseminated intravascular coagulation) 
• Serum biochemistry – changes, if present, are non-specific, but could include: 
o Mild hyperbilirubinemia (common), attributed to systemic inflammation or vasculitis affecting 
hepatic parenchyma; mild increases in hepatic enzyme activities (relatively uncommon) 
o Mild to severe hyperglobulinemia (common) 
o Serum protein electrophoresis typically shows a polyclonal gammopathy and 
hypoalbuminemia; less frequently decreased beta-1 globulins (negative acute-phase 
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proteins) or increased alpha-2 globulins (positive acute-phase proteins) are seen; rarely a 
‘monoclonal’ or restricted oligoclonal gammopathy is noted 62 
▪ The frequency of electrophoretic changes appears to be decreasing over time, 
possibly as clinicians suspect / investigate FIP at an earlier stage in the disease, with 
increased numbers of cats reported with increased alpha-2 globulins without a 
gammopathy, and decreased numbers of cats with solely a gammopathy 63 
o Mild hypoalbuminemia is common, attributed to a combination of a negative acute-phase 
inflammatory response, compensation for hyperosmolarity, protein-losing enteropathy or 
nephropathy, and third spacing (if effusive) 
o Albumin to globulin ratio is usually low (<0.4 likely FIP; >0.8 FIP is unlikely) 64 
o Acute-phase proteins measurements 
▪ Alpha1-acid glycoprotein (AGP), a positive acute-phase protein, is often elevated in 
cats with FIP 65-67 
• AGP >1.5-2 mg/mL is considered supportive of FIP in cases where FIP is 
suspected 65; however, elevations are not specific to FIP, but the greater 
the magnitude of the increase, the more helpful it may be for cases in 
which there is a lower suspicion of FIP 66-69 
• In one study, 85% of cats with FIP (41 of the 48) had AGP >1.5 mg/mL, 
whilst all cats with effusions that were subsequently demonstrated not to 
have FIP (total of 21; 8 with cardiomyopathy, 6 with neoplasia, 5 with 
inflammatory / fibrotic disease, and 2 for which a definitive diagnosis was 
not achieved) had AGP <1.5 mg/mL, suggesting a specificity of 100% at 
this cut-off 65; however, in the same study four of six cats with terminal 
FIV had AGP >1.5 mg/mL 
• In a second study, over 50% of cats with inflammatory disease had AGP 
>1.5 mg/mL 68; they also found that AGP >1.5–2 mg/mL was supportive 
of FIP where pretest probability (defined as the probability of the 
presence of the condition before a diagnostic test) of FIP was high (i.e. 
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signalment, clinical signs, and other clinicopathological changes were 
suggestive of FIP), whilst in cats with a low pretest probability of FIP (i.e. 
few clinical signs nor a signalment suggestive of FIP), only AGP >3 
mg/mL could support a diagnosis of FIP and even then the probability of 
FIP remained <50% 
• In a third study, an optimal cut-off of 2.26 mg/mL achieved a sensitivity of 
85% and specificity of 90% 66; however, a definitive diagnosis (as 
confirmed histologically) was not made for the majority of FIP and non-
FIP cats 
• Cats with non-effusive FIP appear to have similar AGP values as those 
with effusive FIP 67 
• Some authors have found AGP to be particularly useful to support a 
diagnosis of FIP in cases where there was a strong suspicion of FIP, but 
where histology was equivocal 69 
▪ The utility of other positive acute-phase proteins (haptoglobin; serum amyloid A) in 
supporting a diagnosis of FIP has been evaluated 65, 66; although both were 
significantly elevated in cats with FIP, as compared to healthy cats or those with 
cardiac disease, neither was as accurate as AGP in differentiating cats with FIP from 
those with inflammatory diseases (septic processes; retroviral infection; neoplasia) 
Effusion analysis 
• Analysis of FIP-associated effusions (if present) can provide strong support for a 
diagnosis of FIP 
• Basic analysis – often FIP-associated effusions appear clear (i.e. of low 
cellularity), straw-yellow in color (reflecting the hyperbilirubinemia present), and 
viscous (i.e. highly proteinaceous) 
o Total nucleated cell counts often <5 x109/L nucleated cells, comprising predominately non-
degenerate neutrophils and macrophages, with some lymphocytes 
o Protein often >35 g/L (but can be <30 g/L; esp. following repeated drainage) 
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o Similar protein changes to serum 66, 70, 71: often low albumin to globulin ratio  
o Cloudy fluid is sometimes noted 
• The Rivalta test – a simple and inexpensive point-of-care test on effusions 
o Method: mix 8ml distilled water with 1 drop 98% acetic acid (or 2-3 drops white vinegar); 
place 1 drop of effusion onto surface. A positive result is indicated by the effusion drop 
holding its shape. A negative result is indicated by the effusion drop dissipating into solution. 
o Positive results may also result from other inflammatory exudates, such as those found in 
septic peritonitis, cholangiohepatitis and neoplastic effusions 
o The sensitivity of the Rivalta test in correctly identifying cats with FIP varies from 91.3% to 
98% and the specificity from 65.5% to 80% 71, 72 
▪ In one study, where there was a 57% prevalence of FIP, negative and positive 
predictive values were 97% and 86% respectively 71. In a larger more recent study, 
where there was 34.6% prevalence of FIP, negative and positive predictive values 
were 93.4% and 58.4% respectively 72 
▪ A recent study noted that when the Rivalta test was combined with fluid cytology, to 
identify and exclude cases of lymphoma and bacterial peritonitis / pleuritis, both 
specificity and positive predictive values improved (73.0% and 73.4% respectively) 72 
▪ These data suggest that the Rivalta test is most useful as a screening test to rule out 
FIP 
• Measurement of CoV antibodies in effusions – since both false positive (specificity of 86%) and false 
negative (sensitivity of 85%) results occur when  used to predict the presence of FIP 71, this test is 
not recommended (i.e. more accurate tests are available) 
• Measurement of acute phase proteins 66 in effusions – using a cut-off of 1.55 mg/ml for AGP had a 
sensitivity and specificity of 93% in the diagnosis of FIP, based upon results from 14 cats with and 53 
cats without FIP; false-positive results included three cases of septic peritonitis and one retroviral 
positive cat with metastatic abdominal neoplasia. Measurement of haptoglobin and serum amyloid A 
were both less sensitive and less specific. 
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• For discussion of immunostaining and molecular diagnostics of effusions see respective sections 
below 
 
Analysis of cytological samples other than effusions 
• Other bodily fluids (e.g. CSF, aqueous humor) and tissue aspirates (e.g. lymph nodes; mass-lesions) 
can be useful in the diagnosis of FIP 
• Cytology may provide evidence of pyogranulomatous to granulomatous inflammation: consistent 
with, but not diagnostic for, FIP 
o In CSF, non-septic pyogranulomatous (or mixed cellular, but including macrophages) 
inflammation compatible with FIP was present in 76% of the cats with FIP and 30% control 
cats 73. NB: 14 of the 41 cats included in the study had samples collected immediately post-
mortem, whilst the rest were collected during diagnostic investigations. The influence that 
this would have had on results, if any, is unknown 
o In aqueous humor, non-septic pyogranulomatous (or mixed cellular, but including 
macrophages) inflammation compatible with FIP was present in 69% of the 26 cats with FIP, 
but in only one of the 12 control cats 74. NB: All samples were collected post-mortem using a 
larger gauge needle (22G) than would typically be used antemortem (27-29G), which might 
have increased cellular yield 
o On liver and kidney fine-needle aspirates (collected blind from cats with FIP at post-mortem 
examination), cytological sensitivity for non-septic pyogranulomatous inflammation was 82% 
for liver and 42% for kidney aspirates comparable to simultaneously collected needle-core 
biopsies 75; however, eight of the 50 cytological samples were considered ‘not of diagnostic 
quality’ and therefore excluded from calculations. Concurrent samples processed using 
cytocentrifugation of aspirate material suspended in saline were even more likely to be 
considered non-diagnostic (21/32 samples) and of the remainder, all six of the liver aspirates 
but only three of the kidney aspirates revealed pyogranulomatous inflammation 
• For discussion of immunostaining and molecular diagnostics of cytological samples other than 




Tissue biopsy analysis (histology) 
• The primary disadvantage of biopsy analysis is that it requires invasive tissue collection to obtain the 
biopsy 
• In some cats, both with and without FIP, histological examination is equivocal or misleading 45, 69, 76 
o A small number of cats with idiopathic sterile pyogranulomatous inflammation (involving the 
head, neck, or mesenteric lymph-nodes) have also been described, where FIP has been 
excluded, some of which appeared to respond to corticosteroids 77 
• The sensitivity of histology for the diagnosis of FIP in clinical cases is unknown 
o For most studies that evaluate different diagnostic techniques for FIP, inclusion criteria use a 
combination of histology and immunostaining to either confirm FIP or to diagnose an 
alternate pathology on samples collected at post-mortem examination; equivocal cases are 
therefore either not recruited (and not mentioned) or are excluded from further analysis 7 
o In one large study, 14 of 127 recruited cats (11%) were ultimately excluded based upon lack 
of a definitive diagnosis (including histological examination), a further five cats (4%) had not 
had histological examination performed and were also excluded 7 
o In experimental FIP, of 19 cats with effusive disease examined post-mortem all had 
histological lesions (histocytic, neutrophilic, and fibrinous peritonitis) involving the omentum, 
mesentery, and serosal surfaces of the liver, spleen, mesenteric lymph nodes and intestines 
78; however, not all cats had pyogranulomatous lymphadenitis or hepatitis, none had lesions 
within the pulmonary or cardiac tissue (excluding the pericardium), and, in the absence of 
clinical signs or gross evidence of disease, ocular / nervous tissue was not evaluated. 
Restriction of lesions to serosal surfaces would have limited biopsy were these clinical 
cases, despite them all presenting in a similar manner (i.e. all had ascites) 
o Where blind needle-core biopsy of liver and kidneys has been evaluated in cats with FIP, 
possibly a better representation of what would happen clinically (cf. post-mortem derived 
samples), sensitivity has been limited 75. Although all liver biopsies (n=25) were considered 
of diagnostic quality, only 16 (64%) had histological changes consistent with FIP, six were 
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equivocal for FIP, and three contained no lesions supportive of FIP; whilst 7/25 kidney 
biopsies were considered non-diagnostic, and of the ones that were diagnostic only seven 
had histological changes consistent with FIP (28% of total biopsies; 39%), two were 
equivocal for FIP, and nine contained no lesions supportive of FIP 
• For discussion of immunostaining and molecular diagnostics of tissue see respective sections below 
 
Immunostaining for FCoV antigen 
• Immunostaining to assess for the presence of FCoV antigen within infected macrophages 
• These assays include immunocytochemistry (ICC)57 or immunofluorescence 71, 79 of cytological 
preparations (e.g. centrifuge-concentrated cell preparation) or immunohistochemistry (IHC) of 
formalin-fixed cell pellets and tissue 46; monoclonal or polyclonal antibody preparations directed 
against FCoV antigens are used as reagents in these tests 
• Sensitivity of these assays is impacted by both the cellularity of the samples being tested and 
percentage of virus-infected monocytes/macrophages present, since a positive test result depends 
on the detection of FCoV antigen within these cells 
o There appears to be variable geographical availability of immunostaining of cytological 
samples (both effusions and non-effusion samples) as well as differences in techniques 
(particularly the reagents used), sensitivities and specificities between laboratories 
• Immunostaining for FCoV applied to effusions 
o The sensitivity for diagnosis of FIP on immunostaining varies from 57% 57, 71 to 95% 80 
o The specificity for diagnosis of FIP on immunostaining varies from to 71% to 100%  
o False positive results were reported for cats with neoplasia (lymphoma, adenocarcinoma) 
and cardiac disease 57, 71, 81 
o One author described IHC on formalin-fixed cell pellets to be more sensitive than ICC 46 
• ICC for FCoV antigen on cytological samples (both effusions and non-effusion samples), as a marker 
for FIP: a positive result provides support for a diagnosis of FIP, but a negative result does not rule 
out FIP; and as false-positives occur this should not be solely relied upon to make a diagnosis 
• ICC for FCoV applied to cytological samples other than effusions 
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o On CSF, sensitivity for FIP diagnosis was 85% and specificity was 83% 73; however, some 
samples were acellular and therefore excluded from calculations (1/21 of the FIP group and 
2/20 of the control group). The three false-positive results were from a cat with lymphoma, a 
cat with lymphocytic meningoencephalitis, and a cat with hypertensive angiopathy, brain 
hemorrhage. There was no statistical difference between the sensitivities and specificities 
when the cats were further divided into those with or without neurological signs. 
o On aqueous humor, sensitivity was 64% and specificity was 82% 74; however, some samples 
were acellular and therefore excluded from calculations (1/26 of the FIP group and 1/12 of 
the control group). The two false-positive results were from a cat with lymphoma and a cat 
with pulmonary adenocarcinoma.  
o On mesenteric lymph node aspirates (collected under direct visualization at post-mortem 
examination) sensitivity was 53% (16 of 30 cats with FIP were positive) and specificity was 
91% (1 of 11 control cats were positive) 82, with all samples considered to be of diagnostic 
quality. Results of cytological analysis alone were not reported. The one false-positive result 
was from a cat with lymphoma 
o On liver and kidney aspirates only five of the 16 (31%) liver aspirates, and two of the 19 
(11%) kidney aspirates were positive for FCoV antigen 75. No control cats were tested for 
comparison 
o Unfortunately, the number of cases recruited into these studies (for both FIP and non-FIP 
categories) are small, and most are based upon post-mortem collected samples; this 
increases the confidence intervals for both sensitivity and specificity calculations and limits 
evaluation of diagnostic utility 
▪ Ideally large prospective studies would evaluate the utility of immunostaining (and 
molecular diagnostics) on the ante-mortem diagnosis of FIP in cats suspected of 
having FIP 
• IHC for FCoV antigen as a marker for FIP on tissue samples 
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o Many consider the histopathological demonstration of FCoV antigen within macrophages 
associated with (pyo)granulomatous lesions the reference standard for the diagnosis of FIP 
46 
o Distribution of FCoV within lesions can be variable 83, 84 
o In a large study, 62% of post-mortem collected tissue samples from cats with FIP were 
positive for FCoV within lesions 7; however, due to collection methods not all of these tissues 
would have contained gross lesions 
o The sensitivity of IHC on needle-core biopsy tissue samples was poor in the one study that 
has evaluated this: only six of 25 (24%) liver samples were positive and only three of 18 
(17%) diagnostic kidney samples were FCoV antigen positive 75 
 
Molecular diagnostics in the diagnosis of FIP 
• The utility of RT-(q)PCR for FCoV (see Box 1) as a marker for FIP has been investigated for blood, 
effusions, other cytological samples and tissue samples 
o The majority of, but not all, RT-PCR assays utilized in recent studies (and available clinically) 
are quantitative; despite this, only qualitative (i.e. positive or negative) results have been 
used to calculate diagnostic utility and, in some studies, only the qualitative data are reported 
▪ Quantitative results (e.g. copy number boundaries indicating degree of support) have 
not been evaluated for the diagnosis of FIP, although copy numbers are occasionally 
described for different samples and populations 
▪ RT-qPCR for FCoV are preferable to RT-PCR for a variety of reasons primarily 
related to quality control and initial assay optimization (see Box 1) 
o Multiple studies (reviewed elsewhere 47) have shown that use of FCoV RT-qPCR of blood (or 
blood components) for the diagnosis of FIP is often of low sensitivity, even in cats with 
experimental FIP 78, and that false-positives occur in cats without FIP 85  
o RT-PCR for FCoV on effusions 
▪ Sensitivity for diagnosis of FIP varies from 72% to 100% 7, 86, 87 
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▪ Specificity for diagnosis of FIP varies from 83% to 100% 7, 86, 87; although, numbers 
of samples tested in individual studies were often small 
▪ Samples included in these studies were collected both ante-mortem, as part of the 
routine clinical investigation, and at post-mortem examination; the numbers in either 
category were not reported 
o RT-PCR for FCoV on cytological samples other than effusions 
▪ On CSF sensitivity for diagnosis of FIP ranges from 42 to 63% for all cats 7, 88, 89 
(combined total of 25 positive results from 49 cats); where differentiated, cats with 
neurological/ocular manifestations of FIP were more likely to have a positive result 
(86% cf. 17%) than cats without these manifestations 88; specificity was 100% in all 
studies where control cats were tested. In all studies, samples were collected post-
mortem 
▪ On aqueous humor sensitivity for diagnosis of FIP was 25% (4/16 samples; all 
collected post-mortem) 89. No control cats were tested for comparison 
▪ On mesenteric lymph nodes aspirates (collected under direct visualization post 
mortem) sensitivity for diagnosis of FIP ranges from 85% to 90% (17 of 20 cats with 
effusive and non-effusive FIP, and 18 of 20 cats with non-effusive FIP, respectively) 
60, 89 and specificity was 96% (1 out of 26 control cats was positive) 60 
▪ On liver, spleen and popliteal lymph node aspirates (20 of each from cats with either 
effusive and non-effusive FIP; all collected post mortem) sensitivities for diagnosis of 
FIP were 85, 80 and 65% respectively 89. No control cats were tested for comparison 
▪ Unfortunately, the number of cases recruited into these studies (for both FIP and 
non-FIP categories) are small, and most are based upon post-mortem collected 
samples; this increases the confidence intervals for both sensitivity and specificity 
calculations and limits evaluation of diagnostic utility 
• Ideally large prospective studies would evaluate the utility of molecular 
diagnostics (and immunostaining) on the ante-mortem diagnosis of FIP in cats 
suspected of having FIP 
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o RT-PCR for FCoV on tissue samples 
▪ All of these studies comprised samples collected at post-mortem examination 
• Larger volumes of tissue are often collected under these circumstances, which 
may increase the likelihood of achieving a definitive diagnosis and 
consequently the diagnostic sensitivity in cats with FIP 
• Tissues may have been sampled that would not necessarily have been 
collected clinically, potentially reducing diagnostic sensitivity in cats with FIP; 
e.g. liver and spleen biopsy in a cat with solely neurological signs 
• Conversely, samples may be collected from cats with more advanced clinical 
disease and pathological change, potentially increasing diagnostic sensitivity 
in cats with FIP 
▪ In studies comprising more than 20 cats with FIP, sensitivity per cat (i.e. where one 
or more samples were analyzed per cat, and a single positive result considered to be 
diagnostic for FIP) for diagnosis of FIP varied from 94% to 96% 7, 90, whereas when 
samples from individual tissues were considered sensitivity ranged from 88% to 90% 
7, 91; the tissues collected from individual cats (both FIP and non-FIP populations) 
varied widely  
▪ In studies comprising samples from more than 20 cats without FIP, specificity per cat 
(i.e. where one or more samples were analyzed per cat, and a single positive result 
considered to be diagnostic for FIP) ranged from 39% to 90% 7, 90, 92, whereas when 
samples from individual tissues were considered specificity was 92% 7 
▪ Viral copy numbers were generally higher in cats with FIP as compared to those 
found in cats without FIP 7, 90; viral copy numbers were also generally higher in tissue 
samples that were positive for FCoV antigen than for those that were negative for 
FCoV antigen 7 
o Overall, a positive RT-(q)PCR result on effusions, other cytological samples and tissue, but 
not blood (or its constituents), can provide strong support for a diagnosis of FIP; however: 
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▪ Similar to immunostaining testing for FCoV antigen, sensitivity of RT-(q)PCR will be 
affected by the number of FCoV-infected cells present in the sample under test; for 
cytological samples this is influenced by both cellularity and pathology, whereas for 
tissue samples this appears to be a function of pathology distribution 
▪ On effusions and other cytological samples, a negative result does not rule out FIP, 
particularly where cellularity was low; whereas on tissue samples where there is 
supportive pathology a false negative result is rare 7 
▪ Since false-positives occur, RT-(q)PCR should not be solely relied upon to make a 
diagnosis of FIP, particularly if multiple tissue samples are tested (as this can 
increase the likelihood of obtaining a single false-positive result). Fewer false-
positives are documented for cytological samples, likely reflecting their lower 
cellularity as well as expected distribution of potentially infected macrophages; 
however, caution should be used when interpreting specificities for cytological 
samples due to the small sample sizes 
• FCoV mutation analysis has been applied to samples previously determined to be positive by RT-
qPCR (see Box 1) 
o The aim of mutation analysis is to differentiate FCoV pathotypes (i.e. ‘FECV’ from ‘FIPV’), 
based upon differences in the viral genomic sequence, in the hope that this can be used to 
differentiate cats with FIP from those without 39 
o Presence of mutations M1058L and S1060A within the fragment of Spike gene encoding the 
putative fusion peptide of the serotype 1 Spike glycoprotein has been most frequently 
studied for the diagnosis of FIP, albeit using different techniques, different sample types and 
with different conclusions (see Table 2) 
o Inclusion of Spike gene analysis alongside RT-qPCR does not appear to substantially 
improve specificity; further, a consequence of considering only results with Spike gene 
mutation as being diagnostic for FIP significantly reduces test sensitivity 7  
o Detection of Spike gene mutations in cats without FIP was not unexpected, as it is estimated 
that 90% of cats that experience systemic FIPV infection do not go on to develop FIP 36 
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o Some authors remain strongly supportive of the use of Spike gene analysis using allelic 
discrimination in the diagnosis of FIP where minimizing false-positive results is paramount 47 
 
Box 1: Use of PCR in the detection of FCoV 
Polymerase chain reaction (PCR), is the method by which DNA is exponentially amplified using primers to 
target a specific sequence, enabling sensitive detection down to a very low starting DNA copy number. 
Post-PCR amplification processing (e.g. sequencing) can be applied as well if needed. PCR only 
amplifies DNA so because FCoV is an RNA virus a pre-PCR step using a viral enzyme, reverse 
transcriptase, is required to generate a strand of complementary DNA (cDNA) using the original FCoV 
RNA template, in a process known as reverse transcription. A combination of this process and PCR is 
known as Reverse Transcription-Polymerase Chain Reaction (RT-PCR).  
 
Given that only a very small volume of diagnostic sample is ultimately added to each PCR reaction, this 
does result in a limit to PCR sensitivity, although it remains a highly sensitivity modality when compared to 
other tests for the presence of a pathogen. 
 
Due to the high frequency of transcriptional errors during replication of RNA viruses and inherently 
increased variation between viral strains (as compared to replication of DNA viruses), primers designed 
for the detection of FCoV (see Figure 4) predominantly target sections of the genome that are considered 
to be highly conserved (e.g. non-structural protein 7b; the membrane glycoprotein-nucleocapsid protein 
border; 3’ untranslated region), as determined by known sequence comparisons. Due to the conserved 
nature of these sections of the genome, other members of the Alphacoronavirus genus (i.e. canine 
coronavirus, transmissible gastroenteritis virus) may also result in a positive result using assays for FCoV 
93. In contrast, one study described a PCR using primers designed on the more variable envelope protein 
gene on the suspicion that FECV could be differentiated from FIPV based on limited sequence data 94, 
although this is not supported by more recent data 39. The shorter the amplified fragment in PCR, the 
more efficient the assay which contributes to increased sensitivity; however, this does limit the length of 
amplified fragment subsequently available for sequencing if required. Regardless of how good primer 
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design is infrequently genomic variation, even in conserved regions, can result in the failure to detect 
FCoV (i.e. false negative results) even when likely present at high level 7.  
 
Quantitative (sometimes known as real-time) RT-PCR (RT-qPCR) assays, that use either DNA-
intercalation dyes (e.g. SYBR Green) or (TaqMan) hydrolysis probes to quantify the DNA within the 
reaction mixture after every amplification cycle, have been applied to the detection of FCoV 56, 95. If the 
signal from the reaction exceeds a defined threshold it is taken to be a positive result and the cycle 
number at which the sample became positive is usually reported as either a CT (cycle exceeding 
threshold) or CP (crossing point). It should be noted that the lower the CT/CP value the higher the starting 
copy number, such that a CT/CP value of around 20 corresponds to around 106 copies per reaction, 
whereas a CT/CP value of around 40 corresponds to around 10 copies per reaction. Quantitative assays 
are more easily optimized and may result in them being more sensitive than conventional PCRs (which 
rely on detection of DNA at the end of the PCR process). Quantitative assays are also subject to less risk 
of laboratory contamination (a potential cause of false positive results) than conventional PCRs as the 
reaction wells containing amplified DNA remain sealed and do not require opening for completion of 
detection (using a gel for example) as for conventional PCR. In addition, hydrolysis probes have the 
potential to increase assay specificity (cf. use of the PCR amplification primers alone), by providing 
additional nucleotide sequence against which the target sequence must match to obtain a positive result. 
Hydrolysis probes also permit the duplexing of a FCoV assay with another PCR assay such as one for 
the detection of host DNA as an internal control.  
 
As there is a reverse transcription step in the detection of FCoV by PCR, most assays will detect both 
genomic RNA contained within virions and messenger RNA. Produced during active transcription and 
translation of the virus, messenger RNA may be full length or subgenomic-length due to discontinuous 
transcription 96. Relative abundance of individual fragments of the genome may therefore vary within a 
sample dependent upon the nature of the virus within that sample (e.g. cell-free virions vs. cell-associated 
viral replication) 91. This may account for differences in sensitivity between assays targeting different 
sections of the genome. Differences between the structure of subgenomic mRNA and genomic RNA (see 
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Figure 4) have been exploited by some assays 91, 97, with the premise that detection of active viral 
transcription would only be present in cats with FIP; however, positive results were obtained from the 
blood of cats in a small number of cats without FIP 97. 
 
PCR amplified DNA fragments may be sequenced, either by Sanger sequencing or by pyrosequencing. 
This has been applied to the sequence of the FCoV Spike gene associated with a switch in cell tropism, 
(see FCoV mutation analysis) 7, 86, 87. Limitations of Sanger sequencing include lack of data from 
approximately the first 30-50 bases of the fragment, time taken to perform, and need for specialist 
equipment; however, sequencing of relatively large fragments (e.g. up to 1000+ bases) is possible and 
the target sequence does not need to be known. Bench-top pyrosequencing is typically used to rapidly 
sequence short sections (~10-20 bases) on much smaller fragments; this is often facilitated by knowledge 
of the sequence possibilities of this section of the genome. Sanger sequencing has also been applied to 
fragments amplified from different regions of the FCoV genome for phylogenetic comparisons of isolates 
collected from an epizootic outbreak of FIP 98. An alternative method of FCoV mutation analysis, which 
has been applied to FCoV RT-qPCR positive samples, is allelic discrimination 89, 90, 99. This is where two 
probes, each containing a different fluorescent dye, corresponding to the alternative FCoV genomic 
sequence (i.e. one mutated, one not) being targeted are included in an assay, with the ratio of one probe 
to another measured by the relative production of fluorescence during the thermal cycling. 
 
Loop-mediated isothermal amplification (LAMP) is a similar technology to PCR, whereby targeted (c)DNA 
sequences are amplified; however, as amplification is performed at a constant temperature there is no-
longer a requirement for a thermal cycler and is therefore potentially considerably cheaper and more 
robust in the field. DNA amplification is detected by an increase in turbidity often facilitated by the use of 
dyes, and post-amplification processing is limited (i.e. sequencing is not possible). This technology has 
been applied to the detection of FCoV (i.e. RT-LAMP), and although specific (i.e. only samples positive 




Table 1 Overview of diagnostic tests for FIP 1 
Test Sample Target False negatives False positives Comments 
Rivalta’s test 71, 72 Effusion Inflammatory 
proteins 
 Other causes of 
exudate e.g. bacterial 
peritonitis, lymphocytic 
cholangitis 
Cheap, rapid point-of-care test 
Non-specific; little advantage over fluid 
cytology and protein analysis 
Histopathology 7, 83 Tissue Inflammatory 
response to 
FIP 
Tissue sampled not 
involved 
Other causes of 
pyogranulomatous 
inflammation (consider 
tissue culture and 
IHC) 
Systemic perivascular granulomatous 
or pyogranulomatous lesions strongly 
supportive of FIP in conjunction with 
compatible history, clinical signs etc. 
Most pathologists recommend IHC to 
confirm 
FCoV RT-(q)PCR 7, 99 Effusion; CSF; 
aqueous humor; 
tissue aspirates or 
biopsy; (blood = 
very poor sens.) 
FCoV RNA Low cellularity or 
sample degradation; 
lab error (e.g. strain 




Non-specific: should not be used as a 
sole diagnostic test. Positive RT-
(q)PCR on tissue, CSF, aqueous 
humor and effusions is strongly 
supportive of FIP in conjunction with 
compatible history, clinical signs, 
cytology etc. Sens. RT-(q)PCR > IHC  
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In general, samples from cats with FIP 
have higher viral loads than samples 
from cats without FIP that are also 
infected with FCoV.  
FCoV RT-LAMP 100 Effusion, tissue, 
blood 
FCoV RNA Low cellularity or 
sample degradation; 
lab error (e.g. strain 
not detected by PCR 
assay) 
Lab error (e.g. 
contamination) 
Poor sensitivity cf. RT-qPCR; does not 
require expensive equipment to 
perform 
Immunohistochemistry 
(IHC) 7, 83 / 
Immunocytochemistry 










masked by patient’s 




IHC considered reference standard for 
confirmation 
ICC of more limited specificity (lab 
dependent) can be interpreted as 
strongly supportive of FIP in 
conjunction with compatible history, 
clinical signs etc. 
 2 
  3 
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Table 2 Sensitivity (sens.) and specificity (spec.) of different modalities applied to Spike gene mutation analysis. Where specificity is not reported 4 
either no cats without FIP were included in those studies, or the relevant samples from cats without FIP were negative by FCoV RT-qPCR and 5 
therefore Spike gene mutation analysis could not be performed. NA = not available 6 
Methodology Sample type (corresponding sensitivity +/- specificity cf. to FCoV RT-PCR alone) Notes 






Pyrosequencing  Sens. = 81%  
Spec. = 95% 
(cf. 90% and 93% 
respectively) 
14/19 samples 
from cats without 
FIP positive for 
FCoV were also 
positive for the 
Spike gene 
mutation 7 
Sens. = 74%  
Spec. = 96%  
(cf. 91% and 96% 
respectively) 
The one sample from a 
cat without FIP that was 
positive by FCoV RT-
qPCR (of 28 tested) was 
also positive for the 
Spike gene mutation 7 
NA NA NA Spike gene mutations were 
detected in FCoV-positive 
tissue from cats without FIP 
at the same frequency as in 
cats with FIP 
Able to obtain results at very 
low viral loads (down to 1.8 






Sens. = 70%  
Spec. = 88%  
(cf. 91% and 50% 
respectively)  
One cat, of the 
four without FIP 
positive for FCoV 
(of 8 tested), was 
positive for the 
Spike gene 
mutation 86 
Sens. = 40-64%  
Spec. = 83% 
(cf. 72-100% and 83% 
respectively) 86, 87 
The one sample from a 
cat without FIP that was 
positive by FCoV RT-
qPCR (of 6 tested) was 
also positive for the 
Spike gene mutation 86 
NA NA NA  
Allelic 
discrimination 
Sens. = 30-71%  
Spec. = 100%  
(cf. 65-95% and 
90% respectively) 
89, 90 
Sens. = 64-69%  
Spec. = 96% 
(cf. 86-97% and 88% 
respectively) 89, 99 
Sens. = 15-45% 
(cf. 65-85%) 89 
Sens. = 44% 
(cf. 63%) 89 
Sens. = 10% 
(cf. 25%) 89 
The copy number below 
which allelic discrimination is 
not possible is reported to be 
1.5 x106 viral RNA 
equivalents/mL effusion 99; 
samples that are below the 






• Until recently, FIP was considered to be a progressive and ultimately fatal disease in the 9 
overwhelming majority of cases; however, with the advent of novel antiviral medication (i.e. protease 10 
inhibitors and nucleoside analogs), there is an argument to consider FIP as a potentially curable 11 
disease 12 
• A handful of cats are suspected to have been able to confine the disease locally, at least for some 13 
time (months to years) 45, 102 14 
• A paucity of placebo- or ‘current best-treatment’-controlled clinical trials of cats with definitively 15 
diagnosed FIP, along with a lack of licensed drugs with proven efficacy in curing FIP, limits treatment 16 
recommendations 17 
• Supportive care – appetite stimulants (e.g. mirtazapine, up to 2mg/cat/day), vitamin B12 18 
supplementation (0.02mg/kg by weekly subcutaneous injection; or 0.25mg/cat orally once daily), anti-19 
oxidants, fluid therapy 20 
• Benefit of draining effusions is debated 21 
o Thoracocentesis is indicated where dyspnea is present 22 
o Therapeutic abdominocentesis is controversial and may be detrimental due to exacerbation 23 
of dehydration if large volumes are removed (which often reform rapidly) 24 
o Some authors have described fluid drainage followed by intracavitary steroid administration 25 
(dexamethasone 1mg/kg once daily, until resolution of effusion or up to seven days); in one 26 
study where this was administered, in addition to other medications, effusions temporarily 27 
resolved in six of 36 cats, and although all succumbed to FIP (one within 7 days of 28 
diagnosis, four 21 days to 3 months of diagnosis, and one at 200 days post-diagnosis), this 29 
compared favorably with the median survival time of 8-9 days for all cats treated 103 30 
• Prednisolone – is frequently administered to ameliorate some of the clinical signs associated with the 31 
chronic inflammatory process; however, there have been no clinical trials to support its use. A starting 32 
dose of 0.5mg/kg twice daily orally is suggested (some texts suggest up to 1mg/kg twice daily), then 33 
tapered if possible 34 
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o One study found that survival times of cats with non-effusive FIP were significantly 35 
shorter in cats who were treated with corticosteroids (by any route) concurrently with 36 
polyprenyl immunostimulant (median survival time 21.5 days cf. 73.5 days) 59; however, 37 
authors could not rule out administration of corticosteroids as an indirect marker of 38 
disease severity 39 
• Feline interferon-omega – often used but lacked convincing evidence of effect in a placebo-controlled 40 
trial 103 41 
• Many other drugs have been suggested but currently lack a robust evidence base for use including: 42 
pentoxifylline, propentofylline 104, polyprenyl immunostimulant (20% dry FIP cats in recent study had 43 
greater survival than expected, gaining more clinical interest)59, ozagrel hydrochloride 105, 44 
cyclophosphamide, ciclosporin A, anti-TNF- antibodies 106, itraconazole 107, mefloquine 108, turmeric-45 
based compounds 109 and herbal medication 46 
• Protease inhibitor GC376 47 
o The function of the FCoV protease is to cleave the viral polymerase from polyprotein 1, and 48 
is essential for viral replication; GC376 is a reversible, competitive inhibitor of the FCoV 49 
protease 110 50 
o Administered by subcutaneous injection twice daily, GC376 produced remarkable responses 51 
in both experimental and naturally-occurring FIP: six of eight cats with experimentally-52 
induced FIP were alive at 8-months post-treatment 29; and 19 of the 20 cats with naturally-53 
occurring FIP had a positive response (including, where present: rapid resolution of pyrexia; 54 
resolution of effusions and associated clinical signs; resolution of icterus; resolution of 55 
uveitis; resolution of mass lesions; weight gain) (sustained in seven) 58 56 
o Based upon evidence of relapse of clinical signs following withdrawal of short courses of 57 
treatment, followed by a sustained response to re-institution of treatment, in cats with 58 
naturally-occurring FIP, the minimum duration of treatment was increased and is now 59 
recommended as 12 weeks 60 
o Reported side effects of GC376 administration included: injection reactions (transient pain 61 
upon administration; occasional foci of subcutaneous fibrosis; hair loss); and interruption of 62 
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normal dental development in cats aged <4 months (delayed development; abnormal 63 
eruption of permanent teeth) 58 64 
o Eight of the 13 cats that succumbed to naturally-occurring FIP did so due to severe 65 
neurological signs, and although some of these cats had experienced remission of clinical 66 
signs following an increase in dose of GC376 administered, ultimately they relapsed 58. Cats 67 
that had initially presented with neurologic FIP had been excluded from this treatment trial 68 
based upon unpublished experimental studies; presumably poor response to treatment or 69 
high frequency of relapse 70 
• Adenosine nucleoside analog GS-441524  71 
o GS-441524 acts as an alternative substrate and RNA-chain terminator of the viral RNA 72 
polymerase, thereby interfering with viral replication 73 
o Administered by daily subcutaneous injection, GS-441524 produced remarkable responses 74 
in both experimentally-induced and naturally-occurring FIP: all ten cats with experimental-75 
induced FIP were alive at 8 months post-treatment 111; and 26 of 31 cats with naturally-76 
occurring FIP had a positive response (including, where present: rapid resolution of pyrexia; 77 
resolution of effusions and associated clinical signs; resolution of icterus; resolution of 78 
uveitis; resolution of mass lesions; weight gain) (sustained in 25) 112  79 
o Based on evidence of relapse of clinical signs following withdrawal of short courses of 80 
treatment in cats with naturally-occurring FIP treated with GC376 58 and in cats with 81 
experimentally-induced FIP treated with GS-441524 111 (where treatment courses were of 2 82 
weeks, with a repeated course in the two cats that experienced relapses), the minimum 83 
treatment duration for cats with naturally-occurring was set at 12 weeks 84 
o Cats with neurological FIP were associated with a poorer outcome and, where successful, 85 
required increased doses of GS-441524 (continued for a minimum of 12 weeks) to achieve 86 
clinical remission 112, 113 87 
o Reported side effects of GS-441524 administration included 112: injection reactions (transient 88 
pain upon administration, lasting 30-60s; ulcerations, progressing to open sores in some 89 
cats; scar formation); and development of transient azotemia in one cat 90 
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o A rapid, transient rise in serum globulins was also found, associated with resolution of 91 
effusions 92 
• Neither protease inhibitor GC376 nor nucleoside analog GS-441524 are commercially available; 93 
however, there are reports that some owners have sourced “black-market medication” via the internet 94 
(personal communications) 95 
• Mutian® X, an adenosine nucleoside analogue, reported to be different to GS-441524, has been 96 
marketed for the treatment of FIP. Mutian® X is available as both oral and injectable formulations. 97 
Although no evidence has been published to support the use of Mutian® X to date, there is limited 98 
research describing its use to stop fecal shedding of virus 114 99 
• Functional changes to the FCoV genome that resulted in in vitro changes in susceptibility to GC376 100 
have been demonstrated following chronic administration of GC376 to a cat with naturally-occurring 101 
FIP 115; however, this was not accompanied by clinical evidence of drug resistance. This has raised 102 
concerns regarding the potential for emergence of resistance to anti-viral agents, particularly following 103 
chronic administration of treatment or when used in the treatment of enteric FCoV infection (i.e. to 104 
stop fecal shedding) which may ultimately result in the transmission of resistant strains to other cats 105 
 106 
Prognosis 107 
In the absence of GC376 or GS-441524 prognosis associated with FIP is grave (median survival time 9 108 
days; range 3-200 days 103; majority of the cats in that study had effusive disease) 109 
 110 
Prevention 111 
• Vaccination 112 
o Early immunization studies documented ADE 27; whereby cats experimentally sensitized to 113 
one strain of FCoV subsequently developed more acute and severe disease than expected 114 
following exposure to an alternative strain 115 
o An intra-nasal vaccine (FELOCELL FIP, Zoetis), containing a temperature-sensitive, live-116 
attenuated strain of FCoV is available in the USA and continental Europe 117 
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▪ According to manufacturer’s guidelines, cats should be seronegative prior to 118 
vaccination, and  16 weeks at 1st dose, with 2nd dose 3 weeks later 119 
▪ In situations in where FIP is a concern (e.g. catteries were FCoV is endemic), 120 
and therefore vaccination considered, exposure to FCoV will likely have occurred 121 
prior to the earliest recommended age of administration (i.e. 16 weeks) 116 122 
▪ Variable efficacy has been reported; in one study, although vaccination reduced 123 
the risk of developing FIP in those cats that had low or negative FCoV antibody 124 
titers at time of administration (from 10.7% to 3.3%), it did not eliminate the risk 125 
116 126 
▪ ADE has not been reported for the intra-nasal vaccine when administered under 127 
field conditions 116, 117, but was reported under experimental conditions 118 128 
▪ Its use is controversial; and routine use is not recommended even where 129 
available (i.e. it is non-core) 119 130 
▪ It is not possible to differentiate vaccination-induced antibodies from those 131 
acquired following natural exposure, potentially limiting interpretation of 132 
serological antibody testing in the future 133 
• In households or establishments where FIP has been confirmed, efforts should be made to: 134 
o Reduce transmission of FCoV – good litter tray hygiene, provision of adequate numbers of 135 
litter trays, food and water bowls placed away from litter trays (outdoor access for toileting is 136 
preferred) 137 
o Isolation of breeding queens 2 weeks before parturition and separating kittens from the 138 
queens (at 5-6 weeks) before MDA declines to prevent kitten exposure to FCoV has been 139 
described, but is controversial: 140 
▪ Often practically difficult for the breeder to maintain strict biosecurity conditions 141 
▪ Concerns regarding kitten welfare, socialization and development 142 
o Reduce stress – consider stocking density (i.e. keep as low as possible) such as rehoming 143 
non-breeding queens / neuters in breeding environment; maintain stable groups of cats; 144 
consider environmental provisions for each cat and environmental enrichment 145 
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o In domestic households (e.g. <4 cats), it has been suggested not to introduce any new cats 146 
for at least 2-3 months after a cat has died from FIP (to allow time for any residual virus to 147 
become inactive, and to possibly reduce shedding from remaining cats) 120 148 
o In breeding catteries, it is suggested to avoid breeding from cats repeatedly producing kittens 149 
that go on to develop FIP (especially stud males, as these have greater capacity to pass on 150 
their genetic material to future generations); often breeders are unaware (or reluctant to 151 
admit) of having endemic FCoV within their cattery, since FIP typically only manifests after 152 
kittens have been rehomed 153 
o Use of serial fecal PCR to identify chronic FCoV shedders may enable segregation of cats 154 
but intermittent shedding and re-infection with FCoV can occur 155 
 156 
Present relevance and future avenues to consider or to investigate 157 
Questions remain regarding the pathogenesis, diagnosis, treatment and prevention of FIP. Many of the 158 
papers assessing the utility of specific tests to support the diagnosis of FIP (e.g. immunostaining; RT-159 
PCR) have a number of significant limitations such that interpretation of results might not reflect the reality 160 
of clinical practice: 161 
• Many do so in isolation of other supportive results such as clinical history, physical examination 162 
findings, routine clinic-pathological results, and sample cytology or histology 163 
• Samples for testing are frequently obtained at post-mortem examination 164 
• Control populations (i.e. non-FIP cats) might not necessarily represent cats in which FIP was a 165 
significant differential diagnosis (e.g. a middle-aged cat with heart failure and thoracic effusion)  166 
• Numbers of cats enrolled in both FIP and non-FIP populations in many studies that utilize cytological 167 
samples (e.g. fine needle aspirate samples) are small, such that confidence intervals are wide and 168 
strong conclusions difficult to make 169 
• As different papers perform different assays on subtly different populations, comparison of assay 170 
utility on limited numbers of cats remains complicated 171 
Future studies would ideally compare a number of different test modalities and assess their utility in the 172 
diagnosis of FIP, possibly in combination, as part of a diagnostic algorithm applicable to clinical practice, 173 
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where less invasive techniques (e.g. fine-needle aspirates; needle-core biopsy) are preferred. In recent 174 
years there have also been dramatic leaps forward in the treatment of FIP with novel antiviral agents; 175 
more studies are required to determine if these can be curative. Looking forward, advances in knowledge 176 
across all areas, including prevention through vaccination, may occur as a consequence of the SARS-2-177 
CoV outbreak in humans. 178 
 179 
Summary/Discussion  180 
Molecular diagnostics (primarily RT-qPCR) are providing increased support for the diagnosis of FIP, albeit 181 
not a reference standard for diagnosis. Samples suitable for RT-qPCR analysis are more amenable to 182 
minimally invasive diagnostic techniques, as compared to biopsy for histology and confirmatory IHC. In 183 
the advent of effective antiviral medication for the treatment of FIP, the focus of FIP diagnosis will likely 184 
switch to those modalities that maximize sensitivity, from those that maximize specificity. 185 
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Figures 216 
Figure 1 Drawing of a feline coronavirus virion with relative position of structural proteins and genomic 217 
single-stranded RNA (ssRNA) indicated. Modified from Barker & Tasker (Accepted), In Practice. 218 
 219 
Figure 2 Schematic diagram of the feline coronavirus genome with component genes and nucleotide 220 
scale. UTR = untranslated region; nsp = non-structural protein. Modified from Phylogenetic Analysis of 221 
Feline Coronavirus Strains in an Epizootic Outbreak of Feline Infectious Peritonitis by Barker et al. 222 
Journal of Veterinary Internal Medicine 27(3) pp. 445-550. Copyright © 2013 by the American College of 223 
Veterinary Internal Medicine, Wiley-Blackwell. DOI: 10.1111/jvim.12058. 224 
 225 
Figure 3 Suggested diagnostic approach to cats with suspected FIP. Modified from Barker & Tasker 226 




Figure 4 Primer binding sites of selected RT-PCRs: A – amplifying a 295 base pair (bp) fragment of 229 
subgenomic mRNA of the Membrane gene 97; B – amplifying a 688 bp fragment of the Spike glycoprotein 230 
gene 92; C – amplifying a 170 bp fragment of the Envelope protein gene 94; D – amplifying a 171 bp 231 
fragment of the Membrane glycoprotein-Nucleocapsid protein gene border 56; E –amplifying a 102 bp 232 
fragment of the non-structural protein 7b gene 95; and F – amplifying a 223 bp fragment within the 3’ 233 
untranslated region 93. Modified from Phylogenetic Analysis of Feline Coronavirus Strains in an Epizootic 234 
Outbreak of Feline Infectious Peritonitis by Barker et al. Journal of Veterinary Internal Medicine 27(3) pp. 235 
445-550. Copyright © 2013 by the American College of Veterinary Internal Medicine, Wiley-Blackwell. 236 
DOI: 10.1111/jvim.12058. 237 
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